Skip to main content
A new, and as of yet unpublished study, has raised increased concern about the relationship between rofecoxib (Vioxx), Merck’s blockbuster COX-2 inhibitor, and cardiovascular events. The study, which was presented at a meeting in Bordeaux France, was financed by the FDA in collaboration with California’s HMO giant Kaiser Permanente.

Pharmacology Watch: Linking COX-2 Inhibitors and Cardiovascular Event Risk

October 1, 2004

A new, and as of yet unpublished study, has raised increased concern about the relationship between rofecoxib (Vioxx), Mercks blockbuster COX-2 inhibitor, and cardiovascular events. The study, which was presented at a meeting in Bordeaux France, was financed by the FDA in collaboration with Californias HMO giant Kaiser Permanente.